Biocure Technology Inc.
CUREX
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -80.18% | -75.59% | -80.20% | -76.13% | -70.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -80.18% | -75.59% | -80.20% | -76.13% | -70.32% |
| Operating Income | 80.18% | 75.59% | 80.20% | 76.13% | 70.32% |
| Income Before Tax | 60.68% | 93.12% | 94.20% | 82.99% | 82.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 60.68% | 93.12% | 94.20% | 82.99% | 82.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 60.68% | 93.18% | 94.24% | 84.00% | 85.61% |
| EBIT | 80.18% | 75.59% | 80.20% | 76.13% | 70.32% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 72.57% | 94.50% | 95.22% | 89.88% | 90.14% |
| Normalized Basic EPS | 72.97% | 75.05% | 79.92% | 81.17% | 80.11% |
| EPS Diluted | 72.57% | 94.50% | 95.22% | 89.88% | 90.14% |
| Normalized Diluted EPS | 72.97% | 75.05% | 79.92% | 81.17% | 80.11% |
| Average Basic Shares Outstanding | -47.80% | -55.94% | 186.48% | 177.67% | 166.79% |
| Average Diluted Shares Outstanding | -47.80% | -55.94% | 186.48% | 177.67% | 166.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |